Streptozotocin (STZ) targets pancreatic beta cells and can be used in a wide range of dosing patterns that can result in a continuum of diabetic phenotypes, ranging from an early type 2 diabetes profile to complete pancreatic exhaustion representing type 1 diabetes and/or late-stage frank diabetes in a type 2 situation.

Our research team has experience in a wide range of STZ dosing patterns and can help guide your drug discovery efforts accordingly to the appropriate strategy. Discovery Services is also supported by the world’s largest group of certified veterinary pathologists, who have years of experience with pancreatic-specific histology endpoints.